Abstract
Adoptive cell therapy using dendritic cells (DCs) is a strategy to deliver tumor antigens in cancer immunotherapy. Co-delivery of antigens to DC with essential components like genes encoding cytokines, chemokines, and other molecules or stimulation with recombinant cytokines is a potential method for designing an effective tumor vaccine protocol. Here, we describe the stimulation of purified splenic- or bone marrow-derived DC with recombinant interleukin-15 (IL-15) in the presence of intact soluble antigen from metastatic lymphoma tumor cells in an experimental animal model.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519–1526
Banchereau J et al (2001) Dendritic cells as vectors for therapy. Cell 106:271–274
Nestle FO et al (1998) Vaccination of melanoma patients with peptide- or tumor lysatepulsed DCs. Nat Med 4:328–332
Dhodapkar MV et al (1999) Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104:173–180
Zhou Y et al (2002) Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 25:289–303
Schlienger K et al (2003) TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 9(4):1517–1527
Martin JC, O’Brien TJ (2009) Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther 9(6):677–688
Davis ID et al (2003) Rational approaches to human cancer immunotherapy. J Leukoc Biol 73:3–29
Small EJ et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094
Lesterhuis WJ et al (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66(2):118–134
Neves AR et al (2005) Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother 54:61–66
Fabre JW (2001) The allogeneic response and tumor immunity. Nat Med 7:649–652
Suzuki T et al (2005) Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 11:58–66
Yasuda T et al (2007) Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 56:1025–1036
Manna PP et al (2010) Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogeneic effector cell. Vaccine 28:803–810
Manna PP, Mohanakumar T (2002) Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J Leukoc Biol 72(2):312–320
Manna PP, Frazier WA (2003) The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A. J Immunol 170:3544–3553
Lee ET, Wang JW (2003) Statistical methods for survival data analysis, 3rd edn. Wiley, Berlin
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Acknowledgements
This work was supported by a grant from the Department of Science and Technology, New Delhi, India, No. SR/SO/AS-55/2009 (G) and a grant from the Department of Biotechnology, New Delhi, India, No. BT/PR11490/BRB/10/675/2008.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Hira, S.K., Verma, D., Manna, P.P. (2014). Tumor Antigen-/Cytokine-Pulsed Dendritic Cells in Therapy Against Lymphoma. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols